Table 1.
Baseline characteristics - cohort 1 (BORTEJECT trial).
| Parameters | All recipients | KLRC2 wt/wt | KLRC2 wt/del | P value |
|---|---|---|---|---|
| n=86 | n=69 | n=17 | ||
| Characteristics obtained at the time of transplantation | ||||
| Female recipient sex, n (%) | 39 (45) | 33 (48) | 6 (36) | 0.42 |
| Recipient age (years), median (IQR) | 47.3 (35.8–54.0) | 47.7 (35.1–54.1) | 46.2 (40.7–54.8) | 0.63 |
| First renal allograft, n (%) | 61 (71) | 48 (70) | 13 (76) | 0.77 |
| Living donor transplantation, n (%) | 14 (16) | 12 (17) | 2 (12) | 0.74 |
| Donor age (years) a , median (IQR) | 46 (35–58) | 46 (36–58) | 43 (27–56) | 0.49 |
| Cold ischemia time (hours) a , median (IQR) | 12.0 (8.5–17.2) | 12.0 (8.7–17.3) | 12.3 (4.2–16.0) | 0.72 |
| HLA mismatch (A, B, DR) a , median (IQR) | 3 (2-4) | 3 (2-4) | 3 (2-4) | 0.51 |
| CDC-PRA >0% a, n (%) | 30 (37) | 25 (38) | 5 (33) | >0.99 |
| Preformed DSA b, n (%) | 25 (60) | 24 (71) | 1 (13) | 0.004 |
| ABO-incompatible living donor transplant c , n (%) | 1 (1) | 1 (1) | 0 (0) | >0.99 |
| Recipient desensitization, n (%) | 26 (30) | 23 (33) | 3 (18) | 0.25 |
| CDC crossmatch conversion, n (%) | 8 (9) | 7 (10) | 1 (6) | >0.99 |
| CMV status a , n (%) | 0.60 | |||
| R–/D+ | 11 (13) | 10 (15) | 1 (6) | |
| R+/D+ or R+/D– | 58 (70) | 45 (68) | 13 (77) | |
| R–/D– | 14 (17) | 11 (17) | 3 (18) | |
| Characteristics obtained at the time of ABMR screening | ||||
| Time to screening (years), median (IQR) | 4.9 (1.9–12.8) | 5.0 (2.0–13.2) | 4.6 (0.9–12.7) | 0.49 |
| Serum creatinine (mg/dL), median (IQR) | 1.6 (1.2–2.1) | 1.5 (1.2–2.0) | 1.6 (1.3–2.1) | 0.63 |
| eGFR (mL/min/1.73m2), median (IQR) | 54 (32–79) | 54 (31–84) | 52 (32–65) | 0.78 |
| Urinary protein/creatinine ratio (mg/g), median (IQR) | 192 (79–445) | 216 (85–571) | 141 (70–215) | 0.093 |
| Maintenance immunosuppression | ||||
| Triple immunosuppression | 65 (76) | 52 (75) | 13 (77) | >0.99 |
| Dual immunosuppression | 21 (24) | 17 (25) | 4 (24) | >0.99 |
| Tacrolimus | 52 (60) | 43 (62) | 9 (53) | 0.58 |
| Cyclosporine A | 29 (34) | 22 (32) | 7 (41) | 0.57 |
| mTOR inhibitor | 4 (5) | 3 (4) | 1 (6) | >0.99 |
| Belatacept | 1 (1) | 1 (1) | 0 | >0.99 |
| Mycophenolic acid | 71 (83) | 57 (83) | 14 (82) | >0.99 |
| Azathioprine | 5 (6) | 4 (6) | 1 (6) | >0.99 |
| Steroids | 75 (88) | 60 (87) | 15 (88) | >0.99 |
CDC, complement-dependent cytotoxicity; DSA, donor-specific antibody; eGFR, estimated glomerular filtration rate; HLA, human leukocyte antigen; IQR, interquartile range; mTOR, mammalian target of rapamycin; PRA, panel-reactive antibody.
a Donor age, cold ischemia time, HLA mismatch, CDC panel reactivity and CMV status were not recorded for 3, 5, 1, 5, and 3 recipients, respectively.
b Pre-transplant single antigen testing was available for 42 patients (solid-phase HLA antibody screening on the wait list according to our local standard implemented in July 2009). Pre-sensitized patients (until 2009: ≥40% CDC-PRA; since 2009: preformed DSA) were subjected to a protocol of peri-transplant immunoadsorption as earlier detailed.
c This patient underwent desensitization for ABO (AB donor to O recipient) plus HLA antibody (DSA+) barriers.